Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy.
Saved in:
| Title: | Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. |
|---|---|
| Authors: | Yan Z; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China., Li L; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.; University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA., Fu D; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China., Wu W; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China., Qiao N; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China., Huang Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China., Jiang L; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China., Wu D; Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China., Hu Y; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China., Zhang H; Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300070, China., Xu P; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China., Cheng S; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China., Wang L; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China., Lacin S; University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA., Muftuoglu M; University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA., Zhao W; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. zhao.weili@yahoo.com.; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Shanghai, 200025, China. zhao.weili@yahoo.com. |
| Source: | Frontiers of medicine [Front Med] 2023 Aug; Vol. 17 (4), pp. 699-713. Date of Electronic Publication: 2023 Apr 15. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Multicenter Study |
| Journal Info: | Publisher: Higher Education Press Country of Publication: China NLM ID: 101549428 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2095-0225 (Electronic) Linking ISSN: 20950217 NLM ISO Abbreviation: Front Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37060525 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Yan+Z%22">Yan Z</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Li+L%22">Li L</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.; University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Fu+D%22">Fu D</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Wu+W%22">Wu W</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Qiao+N%22">Qiao N</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Huang+Y%22">Huang Y</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Jiang+L%22">Jiang L</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Wu+D%22">Wu D</searchLink>; Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.<br /><searchLink fieldCode="AU" term="%22Hu+Y%22">Hu Y</searchLink>; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.<br /><searchLink fieldCode="AU" term="%22Zhang+H%22">Zhang H</searchLink>; Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300070, China.<br /><searchLink fieldCode="AU" term="%22Xu+P%22">Xu P</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Cheng+S%22">Cheng S</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Wang+L%22">Wang L</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Lacin+S%22">Lacin S</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Muftuoglu+M%22">Muftuoglu M</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Zhao+W%22">Zhao W</searchLink>; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. zhao.weili@yahoo.com.; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Shanghai, 200025, China. zhao.weili@yahoo.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101549428%22">Frontiers of medicine</searchLink> [Front Med] 2023 Aug; Vol. 17 (4), pp. 699-713. <i>Date of Electronic Publication: </i>2023 Apr 15. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Higher+Education+Press%22">Higher Education Press </searchLink><i>Country of Publication: </i>China <i>NLM ID: </i>101549428 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2095-0225 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220950217%22">20950217 </searchLink><i>NLM ISO Abbreviation: </i>Front Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37060525 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s11684-022-0972-8 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 699 Titles: – TitleFull: Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Yan Z – PersonEntity: Name: NameFull: Li L – PersonEntity: Name: NameFull: Fu D – PersonEntity: Name: NameFull: Wu W – PersonEntity: Name: NameFull: Qiao N – PersonEntity: Name: NameFull: Huang Y – PersonEntity: Name: NameFull: Jiang L – PersonEntity: Name: NameFull: Wu D – PersonEntity: Name: NameFull: Hu Y – PersonEntity: Name: NameFull: Zhang H – PersonEntity: Name: NameFull: Xu P – PersonEntity: Name: NameFull: Cheng S – PersonEntity: Name: NameFull: Wang L – PersonEntity: Name: NameFull: Lacin S – PersonEntity: Name: NameFull: Muftuoglu M – PersonEntity: Name: NameFull: Zhao W IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2023 Aug Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2095-0225 Numbering: – Type: volume Value: 17 – Type: issue Value: 4 Titles: – TitleFull: Frontiers of medicine Type: main |
| ResultId | 1 |
